John C.M. Farquhar Sells 9,725 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 9,725 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $25.00, for a total value of $243,125.00. Following the transaction, the chief executive officer owned 571,725 shares of the company’s stock, valued at $14,293,125. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

John C.M. Farquhar also recently made the following trade(s):

• On Tuesday, March 10th, John C.M. Farquhar sold 12,837 shares of Heartflow stock. The stock was sold at an average price of $22.66, for a total transaction of $290,886.42.
• On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.46, for a total transaction of $619,552.52.

Heartflow Stock Performance

NASDAQ HTFL opened at $26.02 on Friday. The firm has a market cap of $2.23 billion and a price-to-earnings ratio of -14.38. The firm has a 50 day simple moving average of $26.86 and a 200-day simple moving average of $30.41. Heartflow, Inc. has a one year low of $20.13 and a one year high of $41.22.

Institutional Investors Weigh In On Heartflow

Large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Heartflow during the 4th quarter worth $27,000. TFC Financial Management Inc. purchased a new position in Heartflow in the third quarter valued at $40,000. Russell Investments Group Ltd. acquired a new stake in Heartflow in the fourth quarter valued at $45,000. Legal & General Group Plc purchased a new stake in Heartflow during the 3rd quarter worth about $59,000. Finally, Strs Ohio acquired a new position in shares of Heartflow during the 4th quarter worth about $99,000.

Analyst Ratings Changes

HTFL has been the subject of several research reports. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company decreased their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday. JPMorgan Chase & Co. cut their price target on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Canaccord Genuity Group increased their price target on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Key Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.